Charis-1000 is under clinical development by Ensol Biosciences and currently in Phase I for Triple-Negative Breast Cancer (TNBC). According to GlobalData, Phase I drugs for Triple-Negative Breast Cancer (TNBC) have an 83% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Charis-1000’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Charis-1000 overview

Charis-1000 is under development for the treatment of metastatic triple negative breast cancer. The drug candidate is developed based on knowledge based in-silico drug discovery (KISDD) technology. It was also under development for the treatment of metastatic cancers including thyroid cancer, melanoma, lung cancer and pancreatic cancer. It is administered through subcutaneous route.

Ensol Biosciences overview

Ensol Biosciences (Ensol) is a bioinformatics and biotechnology company. It develops biological materials based on bioinformatics technology. The company’s biological medicines include anti-degenerative disorder drugs, anti-cancer drugs and antibiotics. It offers services such as in-silico analysis, integrated genome sequencing and analysis, new drug target discovery and new antibiotics target discovery. The company drug pipeline includes musculoskeletal disease, oncology, central nervous system, immunology, animal drugs, rare and intractable disease. Ensol also develops in-silico system infrastructure including bio-server or clouds system implementation. The companies in silico integrated service of genome analysis comprise SGB service, fast and accurate genome sequence analysis, integrated genome analysis service and various analysis services. Ensol is headquartered in Daejeon, South Korea.

For a complete picture of Charis-1000’s drug-specific PTSR and LoA scores, buy the report here.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in its clinical pathway (PTSR), as well as how likely the drug will be approved (LoA). This is based on a proprietary algorithm built from the drugs’ sales forecast, regulatory milestones, cost forecasts, WACC rate and other proprietary data sources found on GlobalData’s Pharmaceutical Intelligence Center.